Leah Lawrence, Author at Oncology Nurse Advisor

Black and White Men Had Similar Outcomes After Radical Prostatectomy

By

Leah Lawrence

April 29, 2021

Black men were less likely to receive androgen deprivation therapy and had lower use of secondary treatment with radiotherapy.

$The management of metastatic breast cancer resistant or refractory to hormonal treatments, while sti$

Breast Cancer

Unplanned Implant Removal Following Treatment for Locally Advanced Breast Cancer

By

Leah Lawrence

April 16, 2021

A team of investigators assessed the frequency and timing of unplanned breast implant removal in patients undergoing with mastectomy, reconstruction, and postmastectomy radiation therapy for locally advanced breast cancer.

This study led to the first clinical trial in humans to test trabectedin for CLL.

Leukemia

Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL

By

Leah Lawrence

April 2, 2021

Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.

Lymphoma

Low-Dose Aspirin Associated With Reduced Likelihood of Non-Hodgkin Lymphoma Diagnosis

By

Leah Lawrence

March 31, 2021

Investigators assessed the association of aspirin, other nonsteroidal anti-inflammatory drugs, and statins with the risk of developing non-Hodgkin lymphoma.

Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of

Head and Neck Cancer

Endoscopic Surgery Improved OS for Locally Recurrent Nasopharyngeal Cancer

By

Leah Lawrence

March 31, 2021

A team of investigators conducted a randomized controlled trial to assess outcomes following salvage endoscopic surgery vs radiation therapy in patients with resectable, locally recurrent nasopharyngeal cancer.

Melanoma

Blood Cell Score for Identifying Aggressive Melanoma

By

Leah Lawrence

March 30, 2021

A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.

Analysis from phase II ENDEAVOR trial showed Kyprolis and dexamethasone superior to Velcade and dexa

Multiple Myeloma

Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients

By

Leah Lawrence

March 25, 2021

A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.

New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.

Skin Cancer

Nomogram Developed to Guide Management of Thin Melanomas

By

Leah Lawrence

March 5, 2021

Using readily available clinicopathologic information, a team of investigators developed a risk calculator to predict disease recurrence in patients with thin melanomas.